The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | The role of clinical trials in improving treatment options for SCD
John James, OBE, Sickle Cell Society, London, UK, briefly discusses treatment options for patients with sickle cell disease (SCD) and the role of the Sickle Cell Society in improving these. While there have been no recent developments in new treatments, Mr James highlights the benefit of the increasing number of clinical trials in this field, and their importance in providing SCD patients with improved therapeutic options. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
